Merck & Co.
AWARDS
NEWS
Four leading pharmaceutical companies partnered with Amazon Web Services and Israel Biotech Fund to launch AION Labs, an innovation space that will allow drug developers to harness AI and computational science to solve therapeutic challenges.
Merck and Acceleron struck an $11.5 billion merger agreement, but before that, rare-disease focused Acceleron Pharma was wooed by multiple suitors, including pharma giant Bristol Myers Squibb.
Today’s approval was based on the Phase III KEYNOTE-826 trial that evaluated Keytruda and chemotherapy with or without bevacizumab compared to the same chemotherapy treatment.
If authorized, it could be available in the U.S. before the end of the year. It is also working to submit applications to other regulators worldwide.
This year – 2021 – will be a transformational year, Rosen predicted, citing three important milestones.
Here’s a look at mRNA vaccines and their effectiveness and more COVID-19 news.
JOBS
IN THE PRESS